Stig Wergeland

2.0k total citations
58 papers, 1.2k citations indexed

About

Stig Wergeland is a scholar working on Pathology and Forensic Medicine, Immunology and Oncology. According to data from OpenAlex, Stig Wergeland has authored 58 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pathology and Forensic Medicine, 15 papers in Immunology and 14 papers in Oncology. Recurrent topics in Stig Wergeland's work include Multiple Sclerosis Research Studies (37 papers), Polyomavirus and related diseases (8 papers) and Neuroinflammation and Neurodegeneration Mechanisms (7 papers). Stig Wergeland is often cited by papers focused on Multiple Sclerosis Research Studies (37 papers), Polyomavirus and related diseases (8 papers) and Neuroinflammation and Neurodegeneration Mechanisms (7 papers). Stig Wergeland collaborates with scholars based in Norway, United States and Denmark. Stig Wergeland's co-authors include Øivind Torkildsen, Kjell‐Morten Myhr, Lars Bø, Rune Midgard, Harald Hovdal, Trygve Holmøy, Kristian S. Bjerve, Antonie Giæver Beiske, Finn Lilleås and Tom Pedersen and has published in prestigious journals such as PLoS ONE, Neurology and Scientific Reports.

In The Last Decade

Stig Wergeland

54 papers receiving 1.2k citations

Peers

Countries citing papers authored by Stig Wergeland

Since Specialization

Citations

This map shows the geographic impact of Stig Wergeland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stig Wergeland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stig Wergeland more than expected).

Fields of papers citing papers by Stig Wergeland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stig Wergeland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stig Wergeland. The network helps show where Stig Wergeland may publish in the future.

Co-authorship network of co-authors of Stig Wergeland

This figure shows the co-authorship network connecting the top 25 collaborators of Stig Wergeland. A scholar is included among the top collaborators of Stig Wergeland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stig Wergeland. Stig Wergeland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation 2025 ·Multiple Sclerosis Journal ·(unknown), Einar August Høgestøl, Øivind Torkildsen, Kjetil Bjørnevik, Jon Michael Gran, (unknown), Marton König, Kjell‐Morten Myhr, Stig Wergeland, Gro Owren Nygaard	0
2	Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety 2025 ·Multiple Sclerosis and Related Disorders ·Magdalena Fossum, (unknown), Jan Aarseth, (unknown), Stig Wergeland, Kjell‐Morten Myhr, Lars Bø, Øivind Torkildsen, Kristin Wesnes	2
3	Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women 2024 ·The Journal of Headache and Pain ·(unknown), Øivind Torkildsen, Jan Aarseth, Marianna Cortese, Trygve Holmøy, Kjell‐Morten Myhr, Trond Riise, Stig Wergeland, Nils Erik Gilhus, Marte‐Helene Bjørk	1
4	An Association of Chitinase-3 Like-Protein-1 With Neuronal Deterioration in Multiple Sclerosis 2023 ·ASN NEURO ·(unknown), Stig Wergeland, Eystein Oveland, Lars Bø	6
5	Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study 2023 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), (unknown), (unknown), Morten Stilund, (unknown), Rikke Ratzer, Jette Lautrup Frederiksen, Nasrin Asgari, (unknown), Henrik Boye Jensen, Matthias Kant, (unknown), Zsolt Illés, Finn Sellebjerg, Melinda Magyari, (unknown), (unknown), Stig Wergeland, Tobias Sejbæk	1
6	The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination 2023 ·PLoS ONE ·(unknown), Stig Wergeland, (unknown), Samih Mohamed‐Ahmed, (unknown), (unknown), Kamal Mustafa, Lars Bø, Christopher Elnan Kvistad	3
7	Safety of breast feeding during rituximab treatment in multiple sclerosis 2022 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Øivind Torkildsen, Kjell‐Morten Myhr, Lars Bø, Stig Wergeland	14
8	Association of adverse childhood experiences with the development of multiple sclerosis 2022 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Øivind Torkildsen, Jan Aarseth, (unknown), (unknown), Elisabeth Gulowsen Celius, Marianna Cortese, Anne Kjersti Daltveit, Trygve Holmøy, Kjell‐Morten Myhr, Trond Riise, Stephan Schüler, (unknown), Stig Wergeland, Nils Erik Gilhus, Marte‐Helene Bjørk	13
9	Perinatal Depression and Anxiety in Women With Multiple Sclerosis 2021 ·Neurology ·(unknown), Øivind Torkildsen, Jan Aarseth, Heidi Øyen Flemmen, Trygve Holmøy, Åslaug Rudjord Lorentzen, Kjell‐Morten Myhr, Trond Riise, (unknown), (unknown), Stig Wergeland, (unknown), (unknown), Nils Erik Gilhus, Marte‐Helene Bjørk	22
10	Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis 2021 ·Multiple Sclerosis and Related Disorders ·Kristin Wesnes, Kjell‐Morten Myhr, Trond Riise, (unknown), Øivind Torkildsen, Stig Wergeland, Trygve Holmøy, Rune Midgard, (unknown), Astrid Edland, Randi Eikeland, (unknown), Hanne F. Harbo, (unknown), (unknown), (unknown), Kjetil Bjørnevik	15
11	Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model 2019 ·Journal of Neuroimmunology ·(unknown), (unknown), Stig Wergeland, Eystein Oveland, Kjell‐Morten Myhr, Lars Bø, Øivind Torkildsen	19
12	Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis 2018 ·Journal of Neuroimmunology ·(unknown), Kjell‐Morten Myhr, Trygve Holmøy, Jūratė Šaltytė Benth, Stig Wergeland, Antonie Giæver Beiske, Kristian S. Bjerve, Harald Hovdal, Rune Midgard, Jørn V. Sagen, Øivind Torkildsen	16
13	1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins 2017 ·Neurochemistry International ·Eystein Oveland, (unknown), Frode S. Berven, Kjell‐Morten Myhr, Øivind Torkildsen, Stig Wergeland	14
14	P587. SuPREMe-CD Study: surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease—preliminary results and trial protocol 2016 ·Journal of Crohn s and Colitis ·(unknown), Katrine Carlsen, Rasmus Goll, (unknown), (unknown), (unknown), Stig Wergeland, Jon Florholmen, Christian Jakobsen, Vibeke Wewer, Lene Riis, Pia Munkholm, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
15	Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis 2015 ·Journal of Neuroimmunology ·Egil Røsjø, Kjell‐Morten Myhr, Kristin I. Løken-Amsrud, S. J. Bakke, Antonie Giæver Beiske, Kristian S. Bjerve, Harald Hovdal, Finn Lilleås, Rune Midgard, Tom Pedersen, Jūratė Šaltytė Benth, Øivind Torkildsen, Stig Wergeland, Annika E. Michelsen, Pål Aukrust, Thor Ueland, Trygve Holmøy	14
16	Fingolimod does not enhance cerebellar remyelination in the cuprizone model 2015 ·Journal of Neuroimmunology ·Maria Nordheim Alme, (unknown), Lars Bø, Kjell‐Morten Myhr, Christian A. Vedeler, Stig Wergeland, Øivind Torkildsen	24
17	Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment 2012 ·Neurology ·Kristin I. Løken-Amsrud, Trygve Holmøy, S. J. Bakke, Antonie Giæver Beiske, Kristian S. Bjerve, Bård Bjørnarå, Harald Hovdal, Finn Lilleås, Rune Midgard, Tom Pedersen, Jūratė Šaltytė Benth, Leiv Sandvik, Øivind Torkildsen, Stig Wergeland, Kjell‐Morten Myhr	90
18	ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study) 2012 ·Archives of Neurology ·Øivind Torkildsen, Stig Wergeland, S. J. Bakke, Antonie Giæver Beiske, Kristian S. Bjerve, Harald Hovdal, Rune Midgard, Finn Lilleås, Tom Pedersen, Bård Bjørnarå, (unknown), (unknown), Jan Schepel, Inge Christoffer Olsen, Kjell‐Morten Myhr	110
19	Polyunsaturated fatty acids in multiple sclerosis therapy 2012 ·Acta Neurologica Scandinavica ·Stig Wergeland, Øivind Torkildsen, Lars Bø, Kjell‐Morten Myhr	19
20	IL‐10 promoter haplotype influence on interferon treatment response in multiple sclerosis 2005 ·European Journal of Neurology ·Stig Wergeland, A. G. Beiske, Harald Nyland, Harald Hovdal, Ditlev Jensen, J. P. Larsen, (unknown), Alf Inge Smievoll, C. A. Vedeler, Kjell‐Morten Myhr	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact